PhorMed has shown promising results with their drug in clinical trials, including high success rates in remission, tumor reduction, and inflammation reduction. They have a strong investor base and are advancing towards Phase 2 trials.
Organizations Involved
Unknown
Founders
Ben Chang, Richard L. Chang, Carole A. Salvador
Company Description
PhorMed is on a mission to bring new hope and a brighter future to patients battling life-threatening diseases. They have raised $3.5 million from over 4,100 investors through crowdfunding and angel investors. Their drug, RP-323, repairs damaged cells and kills cancer. PhorMed is positioned as undervalued with the potential to buy low and sell high compared to similar companies valued between $290M-1.2B.